NCT05149625 Comparison of the Efficacy and Satisfaction of Blood Glucose Management Between Continuous Glucose Monitoring Versus Traditional Self-blood Glucose Measurement in Diabetic Patients After Pancreatectomy
| NCT ID | NCT05149625 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 172 participants |
| Start Date | 2022-11-27 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 172 participants in total. It began in 2022-11-27 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare the efficacy and satisfaction of blood glucose management between continuous glucose monitoring versus traditional self blood glucose measurement in diabetic patients after pancreatectomy.
Eligibility Criteria
Inclusion Criteria: * Patients over 19 years of age * Preoperative diabetes history * Patients who underwent subtotal or total pancreatectomy * Patients who were diagnosed with diabetes mellitus in the evaluation of endocrine function test on the 7th day after pancreaticoduodenectomy, central pancreatectomy, or distal pancreatectomy Exclusion Criteria: * Patients who have used continuous blood glucose measurement device more than once before. * Elderly patients who are not accustomed to using the smartphone applications * Serious systemic diseases that can affect diabetes (chronic kidney disease, heart failure, decompensated liver cirrhosis, etc.) * Steroid user during the study period * Major medical or psychiatric condition that will affect response to treatment
Contact & Investigator
Jin-Young Jang, Dr
PRINCIPAL INVESTIGATOR
Seoul National University Hospital
Frequently Asked Questions
Who can join the NCT05149625 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05149625 currently recruiting?
Yes, NCT05149625 is actively recruiting participants. Contact the research team at jangjy4@gmail.com for enrollment information.
Where is the NCT05149625 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05149625 clinical trial?
NCT05149625 is sponsored by Seoul National University Hospital. The principal investigator is Jin-Young Jang, Dr at Seoul National University Hospital. The trial plans to enroll 172 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.